Immunomedics — Q2 2020 Earnings Presentation
23 slides from Immunomedics's earnings presentation, Aug 5, 2020
Slide 1: Second Quarter 2020 Update
Second Quarter 2020 Update August 5, 2020 Science - Based Innovation - Focused ADC Company
Slide 2: Today's Speakers
Q2 2020 Overview Behzad Aghazadeh, PhD Executive Chairman Today’s Speakers 2 Commercial Update Brendan Delaney Chief Commercial Officer Clinical Update Loretta M. Itri, MD Chief Medical Officer F inancial Update U sama Malik Chief Financial Officer and Chief Business Officer
Slide 3: Forward-Looking Statements
Forward - Looking Statements 3 This presentation and various remarks we make during this presentation, may contain forward - looking statements made pursuant to the Private Securities Litigation Reform Act of 1995. Such statements, including statements regarding expectations for achieving full FDA a
Slide 4: Q2 2020 Overview and Recent Highlights
Q2 2020 Overview and Recent Highlights Behzad Aghazadeh, PhD Executive Chairman
Slide 5: Second Quarter 2020 was Transformative for IMMU
Second Quarter 2020 was Transformative for IMMU 5 FDA approved TRODELVY™ in mTNBC – first drug in Company history 1 2 3 Phase 3 ASCENT topline confirmed compelling safety and efficacy profile of TRODELVY Strong commercial launch of TRODELVY in the United States 4 Balance sheet bolstered with $483 mi
Slide 6: TRODELVY – First ADC Approved Specifically for mTNBC
6 TRODELVY – First ADC Approved Specifically for mTNBC • Approved on April 22, 2020 in U.S. • Strong initial launch execution – Product in channel within one week of approval – NCCN guidelines updated within two weeks of approval • Rapid adoption in advanced mTNBC – $20.1M net sales in first two mon
Slide 7: TRODELVY – First ADC Shown to Improve Clinical Outcomes in Late-Line mTNBC
TRODELVY – First ADC Shown to Improve Clinical Outcomes in Late - Line mTNBC 7 TPC 2 TRODELVY 1.7 Months 5.6 Months ASCENT P3 Topline mPFS HR= 0.41, p<0.0001 1 1: mPFS : median progression free survival; primary endpoint in brain met negative patients 2: Treatment of physician’s choice: eribulin , c
Slide 8: Commercial Update
Commercial Update Brendan Delaney Chief Commercial Officer
Slide 9: TRODELVY's Launch Strategy is Clear
TRODELVY’s Launch Strategy is Clear 1. Establish TRODELVY as a standard of care for 3 rd - line mTNBC • Drive rapid awareness & adoption through product education 2. Optimize positive early clinical experience • Minimize barriers, set clear expectations, educate on adverse event management 3. Become
Slide 10: TRODELVY's Launch Executed with Strong Sense of Urgency
TRODELVY’s Launch Executed with Strong Sense of Urgency □ TRODELVY available in distribution channel within a week of FDA approval □ TRODELVY.com with SEO campaign within hours of approval □ First Peer - to - Peer speaker program executed in week one of launch □ Over 500 attendees for TRODELVY Natio
Slide 11: U.S. Healthcare Professionals Rapidly Gaining Clinical Experience with TRODELVY
Robust adoption in both the community and academic settings (~67% community accounts) U.S. Healthcare Professionals Rapidly Gaining Clinical Experience with TRODELVY 11 * IntrinsiQ survey conducted on June 27th, 2020 NCCN Guidelines were updated to include Sacituzumab - Govitecan on May 8, 2020 >80%
Slide 12: TRODELVY Exceeding Payer 'Time to Review' Benchmarks
TRODELVY Exceeding Payer “Time to Review” Benchmarks • Majority of national and regional payers have implemented TRODELVY coverage policies • Existing TRODELVY coverage policies have limited restrictions • Speed and quality of payer coverage resulting in strong patient access to TRODELVY 12 * * Time
Slide 13: Important News Flow to Maintain Launch Momentum
Important News Flow to Maintain Launch Momentum 13 • ASCENT data presentation, publication and regulatory submission • Expanded clinical experience with TRODELVY in 3 rd - line mTNBC • Branded promotional campaign set to launch in Q3 2020 Robust Sales & Marketing Execution Speed & Quality of Payer C
Slide 14: Clinical Update
Clinical Update Loretta M. Itri, M.D. Chief Medical Officer
Slide 15: Multiple Near-Term Clinical Catalysts – Company Studies
Multiple Near - Term Clinical Catalysts – Company Studies 15 P2 Pivotal Study in mUC • Q3’20 – Submit cohort 1 to ESMO as LBA • Could support AA submission • Enrollment into cohort 3 of CPI - naïve patients underway P2 Trop - 2 - enriched Basket Study • Patient enrollment resumed at select sites • P
Slide 16: Diverse Collaborative Studies to Drive Further Growth
Diverse Collaborative Studies to Drive Further Growth 16 • Collaboration expanded into urothelial cancer and non - small cell lung cancer P2 studies of TRODELVY ± Keytruda in ( i ) 1L PD - L1 – mTNBC (ii) 1L and 2L HR+/HER2 – PD - L1+ mBC P1b/2 MORPHEUS study of Tecentriq + TRODELVY in first - line
Slide 17: Financial Update
Financial Update Usama Malik Chief Financial Officer and Chief Business Officer
Slide 18: Second Quarter 2020 Financial Results
Second Quarter 2020 Financial Results Statement of Operations Three Months Ended June 30, 2020 Three Months Ended June 30, 2019 Revenues TRODELVY Net Sales $20.1M - Total Revenues $20.1M - Expenses Cost of Goods Sold $1.7M - R&D $42.6M $52.9M SG&A $28.9M $14.2M Total Expenses $73.1M $67.2M Net Loss
Slide 19: Balance Sheet and Financial Guidance
Balance Sheet and Financial Guidance Balance Sheet June 30, 2020 March 31, 2020 Cash, cash equivalents, and marketable securities $975.5M* $540.6M Basic shares outstanding 231M 214M Fully diluted shares 242M 225M 19 Projected financial resources adequate to support planned operations into 2021, incl
Slide 20: Concluding Remarks
Concluding Remarks Behzad Aghazadeh, PhD Executive Chairman
Slide 21: TRODELVY Approval in mTNBC is Catalyst that Drives Multiple Initiatives
TRODELVY Approval in mTNBC is Catalyst that Drives Multiple Initiatives 21 TRODELVY Approval
Slide 22: Question & Answer
Question & Answer Immunomedics
Slide 23: Second Quarter 2020 Update
Second Quarter 2020 Update August 5, 2020 Science - Based Innovation - Focused ADC Company